Nilotinib-Induced Thromboembolic Events: A Case Study
Zahra Kmira *
Department of Clinical Hematology, Farhat Hached University Hospital, Sousse, Tunisia.
Ben Yahya Noura
Department of Clinical Hematology, Farhat Hached University Hospital, Sousse, Tunisia.
Guermazi Monia
Department of Clinical Hematology, Farhat Hached University Hospital, Sousse, Tunisia.
Fathallah Neila
Department of Pharmacology, Farhat Hached University Hospital, Sousse, Tunisia.
Atig Amira
Department of Internal Medicine, Farhat Hached University Hospital, Sousse, Tunisia.
Chembah Wafa
Department of Clinical Hematology, Farhat Hached University Hospital, Sousse, Tunisia.
Thabet Maissa
Department of Internal Medicine, Farhat Hached University Hospital, Sousse, Tunisia.
Zaier Monia
Department of Clinical Hematology, Farhat Hached University Hospital, Sousse, Tunisia.
Ben Youssef Yosra
Department of Clinical Hematology, Farhat Hached University Hospital, Sousse, Tunisia.
Haifa Regaieg
Department of Clinical Hematology, Farhat Hached University Hospital, Sousse, Tunisia.
Khelif Abderrahim
Department of Clinical Hematology, Farhat Hached University Hospital, Sousse, Tunisia.
*Author to whom correspondence should be addressed.
Abstract
Nilotinib has significantly improved the treatment of chronic myeloid leukemia (CML) by offering enhanced efficacy and tolerability. However, studies have revealed a concerning link between nilotinib and an increased risk of thromboembolic events, even compared to other tyrosine kinase inhibitors (TKIs). This case report presents a forty-four-year-old male with CML treated with nilotinib, who developed dyslipidemia and multiple arterial occlusive events, including renal thrombosis and carotid artery atheroma. The potential mechanisms underlying nilotinib-induced thromboembolic events are endothelial cell dysfunction, altered lipid metabolism, and pro-inflammatory and prothrombotic effects. Identifying preexisting cardiovascular risks and implementing proactive measures may aid in reducing the occurrence of thromboembolic events in high-risk patients treated with nilotinib.
Keywords: Nilotinib, thromboembolic events, outcome